In this retrospective study, all-female patients with iron deficiency anemia treated with ferric carboxymaltose experienced rapid symptom resolution and increased ferritine and hemoglobin levels, with some reporting manageable side effects such as rash and headache.
June 2026 in “Scholars Journal of Medical Case Reports” This retrospective study found that intravenous iron therapy significantly improved hair loss in most patients with iron deficiency, achieving complete resolution in 60%, partial improvement in 36%, and persistent hair loss in only 4% after three months.
November 2018 in “Springer eBooks” Children need early diagnosis and treatment for iron-deficiency anemia to prevent learning problems and promote health.
February 2018 in “The American Journal of Gastroenterology” This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.
January 2018 in “Journal of Crohn s and Colitis” This study found that high-dose intravenous ferric carboxymaltose may reduce inflammatory activity in patients with inflammatory bowel disease and iron deficiency anaemia, as evidenced by decreased CRP levels and improved clinical disease indices.